Metlife (MET) is trading -4.59 percent lower on Monday 26th of October and has a trading volume of USD 592.2 mn
MetLife shares dip 4.6%, now at $100.17, amid latest stock data and a promising Phase III trial combining osimertinib with savolitinib for MET‑driven lung cancer patients.
3 minutes to read





